Taken together, these results suggested that GVAX therapy leads to an increased CD8+ T cell presence in the TME; however, it does not enhance the general IFNγ production in these CD8+ TILs, in spite of enhancing the tumor-specific IFNγ production. The gene discussed is CD8A; the disease is neoplasm.